Reply to: Association between nilotinib-induced hyperbilirubinemia and UGT1A1 polymorphisms in a chronic myeloid leukemia patient [0.03%]
对慢性粒细胞白血病患者尼洛替尼诱导的高胆红素血症与UGT1A1多态性关联的回复
Daniele Cattaneo,Alessandra Iurlo
Daniele Cattaneo
Multimodal treatment with cisplatin for metastatic disease in malignant peripheral nerve sheath tumors: a case report and review [0.03%]
多模式顺铂治疗恶性外周神经鞘瘤转移病灶的病例报道及文献回顾
Rossella Hakim,Maria Cristina Salone,Giovanni Bozza et al.
Rossella Hakim et al.
Malignant peripheral nerve sheath tumors (MPNSTs) are rare and have among the worst prognoses among all soft tissue sarcomas, with 5-year overall survival rates ranging from 16 to 52%. We report a case of a 50-year-old man with localized do...
Efficacy of immune checkpoint inhibitors rechallenge and metronomic cyclophosphamide with or without bevacizumab in metastatic nonsmall cell lung cancer [0.03%]
免疫检查点抑制剂再挑战和联合或不联合贝伐珠单抗的小剂量环磷酰胺治疗晚期非小细胞肺癌的疗效
Aram A Musaelyan,Svetlana V Odintsova,Magaripa A Urtenova et al.
Aram A Musaelyan et al.
Objective: The present study aims to evaluate the efficacy of immune checkpoint inhibitor (ICI) rechallenge in combination with metronomic cyclophosphamide, with or without bevacizumab, in patients with metastatic nonsmal...
Palbociclib stimulates CD8+ T cell response in triple-negative breast cancer via regulating phosphoglycerate dehydrogenase [0.03%]
帕博西尼通过调节磷酸甘油酸脱氢酶刺激三阴性乳腺癌的CD8+T细胞反应
Yuanyuan Sun,Yaqing Li,Yunwei Han et al.
Yuanyuan Sun et al.
CDK4/6 inhibitors are applied for the treatment of breast cancer. The purpose of this study was to explore the effects of palbociclib (PALB) on triple-negative breast cancer. An in vivo assay was applied to determine the effects of PALB on ...
Deubiquitinating enzyme UCHL1 stabilizes CAV1 to inhibit ferroptosis and enhance docetaxel resistance in nasopharyngeal carcinoma [0.03%]
脱泛素酶UCHL1通过稳定CAV1抑制鼻咽癌铁死亡并增强其多西他赛耐药性
Yixian Ye,Peng Wang,Daquan Wu et al.
Yixian Ye et al.
The overexpression of CAV1 in many cancers is linked to chemotherapy resistance, but the exact mechanisms by which CAV1 contributes to resistance in nasopharyngeal carcinoma (NPC) are not fully known. Our research aims to elucidate the pote...
Enhanced plasma and brain concentrations and medulloblastoma cytotoxicity of asciminib and nilotinib by P-glycoprotein inhibition with tariquidar [0.03%]
塔拉曲班抑制P-糖蛋白可增强艾西明和尼洛替尼在血浆、大脑和髓母细胞瘤中的浓度及细胞毒性作用
Eric M Thompson,Lin Cheng,Ivan Spasojevic
Eric M Thompson
ABL1 and ABL2 are putative drivers of medulloblastoma leptomeningeal dissemination. ABL1/ABL2 inhibitors, nilotinib and asciminib, are P-glycoprotein substrates. The purpose of this work is to elucidate P-glycoprotein expression in the brai...
9-Hexadecenoic acid inhibits the aggressiveness of gastric cancer via targeting PTPN1/FTH1 signaling [0.03%]
十六烯酸通过靶向PTPN1/FTH1信号抑制胃癌的侵袭性
Xin Wang,Haiyan Peng
Xin Wang
9-Hexadecenoic acid (9-HA) possesses anti-tumor properties. However, the effects of 9-HA on gastric cancer are scarcely reported. The present study aimed to investigate the effects of 9-HA on gastric cancer. mRNA levels were detected by rev...
Complete regression of choroidal metastases from renal cancer under sunitinib with grade 3 hyperbilirubinemia [0.03%]
索拉非尼致重度高胆红素血症时转移至脉络膜的肾癌完全退化
Wala Ben Kridis,Raafat Ben Lassoued,Amira Trigui et al.
Wala Ben Kridis et al.
Sunitinib is a small molecule tyrosine kinase inhibitor that is taken by mouth. It works against several kinases, such as vascular endothelial growth factor receptor, c-Kit, and platelet-derived growth factor receptor. We report a case of t...
A fatty acid metabolism-related gene signature can predict poor prognosis in glioma [0.03%]
与脂肪酸代谢相关的基因特征可以预测胶质瘤的不良预后
Chuanyu Li,Xinran Xue,Jiahui Kong et al.
Chuanyu Li et al.
Gliomas, arising from supportive glial cells in the central nervous system, present significant challenges in oncology due to their varying aggressiveness and poor prognosis, particularly in high-grade forms. Understanding the molecular pat...
Impact of obesity on cancer therapy outcomes: a multicenter cohort study of 30-day mortality and morbidity [0.03%]
肥胖对癌症治疗结局的影响：一项关于30天死亡率和发病率的多中心队列研究
Emad Tashkandi
Emad Tashkandi
Obesity is a substantial concern in oncology, influencing cancer characteristics and treatment outcomes. This study investigated whether obesity contributes to increased 30-day mortality and morbidity in patients receiving anticancer therap...